Cefmenoxime
From Wikipedia, the free encyclopedia
Cefmenoxime
|
|
Systematic (IUPAC) name | |
(6R,7R)-7-{[(2E)-2-(2-amino-1,3-thiazol-4-yl)- 2-methoxyimino-acetyl]amino}-3-[(1-methyltetrazol- 5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0] oct-2-ene-2-carboxylic acid |
|
Identifiers | |
CAS number | |
ATC code | J01 |
PubChem | |
DrugBank | |
Chemical data | |
Formula | C16H17N9O5S3 |
Mol. mass | 511.562 g/mol |
Pharmacokinetic data | |
Bioavailability | 100% (given IM) |
Protein binding | 50% to 70% |
Metabolism | Negligible |
Half life | 1 hour |
Excretion | Renal, unchanged |
Therapeutic considerations | |
Pregnancy cat. |
? |
Legal status | |
Routes | Intramuscular, intravenous |
Cefmenoxime is a third-generation cephalosporin antibiotic.
[edit] External links
- DDB 30892
- Yokota N, Koguchi M, Suzuki Y, Fukayama S, Ishihara R, Deguchi K, Oda S, Tanaka S, Nakane Y, Fukumoto T (1995). "Antibacterial activities of cefmenoxime against recent fresh clinical isolates from patients in sinusitis". Jpn J Antibiot 48 (5): 602–9. PMID 7637194.
- Paladino J, Fell R (1994). "Pharmacoeconomic analysis of cefmenoxime dual individualization in the treatment of nosocomial pneumonia.". Ann Pharmacother 28 (3): 384–9. PMID 8193431.
- Duncker G, Reich U, Krausse R (1994). "Cefmenoxime in corneal organ culture.". Ophthalmologica 208 (5): 262–6. PMID 7816419.
|